VELVET LIFT™
Triple-Pathway Eye & Contour Cream
Three expression-line pathways. One eye cream.
Price
$118
Size
15 ml / 0.51 fl oz
The only eye cream targeting three independent expression-line pathways simultaneously — SNARE inhibition (Snap-8™ NP), enkephalin amplification (Leuphasyl®), and nicotinic receptor blockade (Syn®-AKE) — alongside Eyeseryl® and Haloxyl™ for puffiness and dark circles.
Triple-pathway expression line: SNARE inhibition (Snap-8™ NP) + enkephalin amplification (Leuphasyl® SLN) + nicotinic receptor blockade (Syn®-AKE)
Reduces under-eye puffiness by up to 70% in 28 days (Eyeseryl®)
Fades dark circles caused by hemoglobin and bilirubin pigmentation (Haloxyl™)
52% wrinkle reduction in 28 days via Syn®-AKE nicotinic receptor blockade (DSM-Firmenich)
63% reduction in crow's feet via Snap-8™ NP SNARE inhibition
SPP-conjugated Eyeseryl® for 3–8× deeper periorbital delivery
Postbiotic amplifier increases peptide receptor expression by up to 60%
Safe for contact lens wearers
Clinical Results Timeline
What to Expect
Week 1–2
Immediate cooling and de-puffing effect on application. Skin around eyes feels more hydrated.
Week 3–4
Visible reduction in puffiness. Dark circles begin to lighten.
Week 5–8
Crow's feet measurably reduced. Upper eyelid appears lifted.
Week 9–12
Comprehensive rejuvenation of the eye area. Dark circles significantly faded.
The eye area ages 10× faster than the rest of the face. VELVET LIFT™ 2026 is the only eye cream in the world targeting three independent expression-line pathways simultaneously: (1) SNARE complex inhibition via Snap-8™ NP (Acetyl Hexapeptide-8 nanoparticles, Lipotec/Lubrizol) — blocks the SNAP-25 protein that triggers muscle contraction; (2) enkephalin amplification via Leuphasyl® SLN (Pentapeptide-18 in solid lipid nanoparticles) — reduces neuronal activity via the opioid receptor pathway; and (3) nicotinic acetylcholine receptor blockade via Syn®-AKE (DSM-Firmenich) — mimics Waglerin-1 from Temple Viper venom to block the nicotinic receptor at the neuromuscular junction, a completely different molecular target from pathways 1 and 2. All three mechanisms are additive. Eyeseryl® reduces fluid accumulation; Haloxyl™ targets hemoglobin pigmentation; Matrixyl 3000 HP rebuilds the periorbital collagen matrix. Reformulated in 2026 with SPP conjugation on Eyeseryl® for 3–8× deeper periorbital penetration and Lactobacillus Ferment Lysate postbiotic amplifier.
| INCI Name | Common Name | Benefit | Concentration |
|---|---|---|---|
| Aqua | Water | Solvent base | — |
| Lactobacillus Ferment Lysate | Postbiotic Amplifier (Givaudan) | Postbiotic peptide amplifier — upregulates peptide receptor expression in periorbital keratinocytes by up to 60%, amplifying the efficacy of Eyeseryl® and Haloxyl™. INCI-listed, CIR-reviewed, IECIC-confirmed. Globally compliant. | 3% |
| Acetyl Tetrapeptide-5 (SPP-Conjugated, Liposomal) | Eyeseryl® Liposome — SPP-Enhanced | Signal peptide in phospholipid liposome — reduces periorbital fluid accumulation and glycation-induced puffiness; liposomal encapsulation ensures 6–8 hour sustained release in the delicate periorbital zone; clinically proven 70% reduction in under-eye puffiness in 28 days | 4% |
| Palmitoyl Oligopeptide (Liposomal) | Haloxyl™ (part 1) Liposome | Enzyme inhibitor in phospholipid liposome (CMO-encapsulated) — reduces hemoglobin and bilirubin pigmentation responsible for dark circles; liposomal delivery ensures sustained enzymatic activity over 6–8 hours | 2% |
| Hydroxypropyl Cyclodextrin (and) Palmitoyl Tetrapeptide-7 | Haloxyl™ (part 2) HP | Signal peptide in cyclodextrin complex (Croda/Sederma) — anti-inflammatory; reduces hemosiderin deposits causing dark discolouration; cyclodextrin ensures sustained release over 6–8 hours | 2% |
| Hydroxypropyl Cyclodextrin (and) Palmitoyl Tripeptide-1 | Matrixyl 3000 HP | Signal peptide in cyclodextrin complex (Croda/Sederma) — stimulates type I collagen and fibronectin to firm and thicken the delicate periorbital skin; sustained release over 6–8 hours | 3% |
| Acetyl Hexapeptide-8 (Nanoparticle) | Snap-8™ NP | Neurotransmitter inhibitor in polymeric nanoparticles (Lipotec/Lubrizol) — extended Argireline® analogue; blocks SNAP-25 at the SNARE complex; nanoparticle encapsulation extends crow's feet and upper eyelid activity to 8+ hours; reduces expression lines by up to 63% | 3% |
| Pentapeptide-18 (SLN-Encapsulated) | Leuphasyl® SLN | Neurotransmitter inhibitor in solid lipid nanoparticles — mimics endogenous enkephalins to reduce neuronal activity via the opioid receptor pathway; completely different mechanism from SNARE inhibition; SLN encapsulation provides sustained release over 8+ hours; synergistic with Snap-8™ NP | 2% |
| Dipeptide Diaminobutyroyl Benzylamide Diacetate | Syn®-AKE (DSM-Firmenich) | Nicotinic acetylcholine receptor blocker (DSM-Firmenich) — mimics Waglerin-1 from Temple Viper venom; blocks the nicotinic receptor at the neuromuscular junction, the third and final independent expression-line pathway; oil-soluble, formulated in the emollient phase; clinically proven 52% wrinkle reduction in 28 days | 4% |
| Caffeine | Caffeine | Vasoconstriction and lymphatic drainage; reduces periorbital oedema within 15 minutes of application | 2% |
| Sodium Hyaluronate | Hyaluronic Acid (Low MW) | Penetrates deeper into periorbital dermis for targeted hydration | 1.5% |
| Shea Butter | Shea Butter | Emollient, nourishing, barrier protection | 5% |
| Tocopherol | Vitamin E | Antioxidant protection against UV-induced periorbital damage | 1% |
| Phenoxyethanol | Preservative | Preservation | 0.9% |
Complete the Ritual
